Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer

Social Science and Medicine

Volumn 71, Issue 9, 2010, Pages 1548-1556

  Jordens, Christopher F C ^a   Morrell, Bronwen ^a   Harnett, Paul ^b   Hobbs, Kim ^b   Mason, Catherine ^c   Kerridge, Ian H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c South Western Sydney Local Health Network   (Australia)

Author keywords

Anxiety; Australia; CA125 Antigen; Decision making; Medical gaze; New South Wales; Ovarian neoplasms; Surveillance

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CA 125 ANTIGEN;

ANTIGEN; CANCER; DECISION MAKING; MEDICINE; MONITORING; PHILOSOPHY; PROTEIN;

ADULT; AGED; ANXIETY; ANXIETY DISORDER; ARTICLE; ATTITUDE TO ILLNESS; AUSTRALIA; CANCER EPIDEMIOLOGY; CLINICAL ARTICLE; CLINICAL DECISION MAKING; DEPRESSION; DISEASE SURVEILLANCE; FEMALE; HEALTH EDUCATION; HEALTH SERVICE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; OVARY CANCER; PATIENT ATTITUDE; PATIENT COUNSELING; PSYCHOMETRY; SCORING SYSTEM; SEMI STRUCTURED INTERVIEW; TREATMENT PLANNING;

ANXIETY; AUSTRALIA; CA-125 ANTIGEN; DECISION MAKING; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PATIENT EDUCATION AS TOPIC; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; PSYCHOMETRICS; QUALITATIVE RESEARCH;

AUSTRALIA;

EID: 77957713378     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2010.07.033     Document Type: Article

References (22)

1. Armstrong D. Bodies of knowledge: Foucault and the problem of human anatomy. Sociological theory and medical sociology 1987, London, Tavistock, New York. G. Scambler (Ed.).
2. Armstrong N., Murphy E. Weaving meaning? An exploration of the interplay between lay and professional understandings of cervical cancer risk. Social Science & Medicine 2008, 67:1074-1082.
3. Breaden K. Cancer and beyond: the question of survivorship. Journal of Advanced Nursing 1997, 26(5):978-984.
4. Chitale R. Monitoring ovarian cancer: CA125 trial stirs controversy. Journal of the National Cancer Institute 2009, 101:1233-1234.
5. Foucault M. The birth of the clinic: An archaeology of medical perception 1976, (A.M. Sheridan, Trans.), Tavistock, London.
6. Gadducci A., Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Critical Reviews in Oncology/Haematology 2009, 71:43-52.
7. Goonewardene T.I., Hall M.R., Rustin G.J. Management of asymptomatic patients of follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncology 2007, 8:813-821.
8. Hamm R., Smith S. The accuracy of patients' judgements of disease probability and test sensitivity and specificity. The Journal of Family Practice 1998, 47:44-52.
9. Harries M., Gore M. Part II: chemotherapy for epithelial ovarian cancer - treatment of recurrent disease. The Lancet Oncology 2002, 3:537-545.
10. Heaton J. The gaze and visibility of the carer: a Foucauldian analysis of the discourse of informal care. Sociology of Health & Illness 1999, 2:759-777.
11. Hennekens C.H. Epidemiology in medicine 1987, Little, Brown, Boston.
12. Hennessy B.T., Coleman R.I., Markman M. Ovarian cancer. Lancet 2009, 374:1371-1382.
13. Little J.M., Jordens C., Paul K., Montgomery K., Philipson B. Liminality: a major category of the experience of cancer illness. Social Science & Medicine 1998, 47:1485-1494.
14. Moore A., Candlin C., Plum G. Making sense of HIV related viral load: one expert or two?. Culture, Health and Sexuality 2001, 3:429-450.
15. Palmer C., Pratt J., Basu B., Earl H. A study to evaluate the use of CA125 in ovarian cancer follow-up: a change in practice led by patient preference. Gynaecologic Oncology 2006, 101:4-11.
16. Parker P., Kudelka A., Basen-Engquist K., Kavanagh J., de Moor J., Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynaecologic Oncology 2006, 100:495-500.
17. Parsons T. The social system 1951, Routledge & Kegan Paul, London.
18. Prasad A. Making images/making bodies: visibilising and disciplining through magnetic resonance imaging (MRI). Science, Technology, & Human Values 2005, 30:291-316.
19. Rendell J. A testimony to Muzil: Herve Guibert, Foucault, and the medical gaze. Journal of Medical Humanities 2004, 25:33-45.
20. Rustin G.J., Nelstrop A.E., Bentzen S.M., Piccart M.J., Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Annals of Oncology 1999, 10(Suppl. 1):S21-S27.
21. Rustin G.J., van der Burg M.E. A randomised trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators. (MRC OV05/EORTC 55955 trials). Journal of Clincial Oncology 2009, 27(Suppl):1. on behalf of MRC and EORTC collaborators, (abstr).
22. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 1983, 67:361-370.